Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

NOPERTEN 5 TABLET 5 mg - HSA Drug Approval Details

Approvals/HSA/NOPERTEN 5 TABLET 5 mg

Approved

THERAPEUTIC

NOPERTEN 5 TABLET 5 mg

PT DEXA MEDICA (INDONESIA REP OF)🇸🇬 Health Sciences Authority

Approval Date: Jul 1, 2002
Approval ID: 290f471ed9ca01da
Company: PT DEXA MEDICA (INDONESIA REP OF)
Type: Therapeutic

Approval Details

Approval Id: 290f471ed9ca01da
Drug Name: NOPERTEN 5 TABLET 5 mg
Product Name: NOPERTEN 5 TABLET 5 mg
Approval Number: SIN12005P
Approval Date: 2002-07-01
Registrant: GLORIOUS DEXA SINGAPORE PTE. LTD.
Licence Holder: APOTHECA MARKETING PTE LTD
Drug Type: Therapeutic
Forensic Classification: Prescription Only
Dosage Form: TABLET
Route Of Administration: ORAL
Atc Code: C09AA03
Atc Item Name: lisinopril
Pharma Manufacturer Name: APOTHECA MARKETING PTE LTD
Company Detail Path: /organization/apotheca-marketing-pte-ltd

Active Ingredients

LISINOPRIL

5 mg

LISINOPRIL

5 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jul 1, 2002

Approval ID

290f471ed9ca01da

Type

Therapeutic

Back to HSA Approvals